Filing Details

Accession Number:
0001104659-19-032917
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-05-30 21:26:55
Reporting Period:
2019-05-28
Accepted Time:
2019-05-30 21:26:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1761612 Bicycle Therapeutics Plc BCYC () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1460732 Sv Life Sciences Fund V Lp C/o Bicycle Therapeutics Plc
B900, Babraham Research Campus
Cambridge X0 CB22 3AT
No No Yes No
1482194 Sv Life Sciences Fund V Strategic Partners, L.p. C/o Bicycle Therapeutics Plc
B900, Babraham Research Campus
Cambridge X0 CB22 3AT
No No Yes No
1644146 Sv Life Sciences Fund V (Gp), Lp C/o Bicycle Therapeutics Plc
B900, Babraham Research Campus
Cambridge X0 CB22 3AT
No No Yes No
1644160 Svlsf V, Llc C/o Bicycle Therapeutics Plc
B900, Babraham Research Campus
Cambridge X0 CB22 3AT
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2019-05-28 874,709 $0.00 874,709 No 4 C Indirect By SV Life Sciences Fund V, L.P.
Ordinary Shares Acquisiton 2019-05-28 623,196 $0.00 1,497,905 No 4 C Indirect By SV Life Sciences Fund V, L.P.
Ordinary Shares Acquisiton 2019-05-28 18,485 $0.00 18,485 No 4 C Indirect By SV Life Sciences Fund V Strategic Partners. L.P.
Ordinary Shares Acquisiton 2019-05-28 13,169 $0.00 31,654 No 4 C Indirect By SV Life Sciences Fund V Strategic Partners. L.P.
Ordinary Shares Acquisiton 2019-05-28 377,732 $14.00 1,875,637 No 4 P Indirect By SV Life Sciences Fund V, L.P.
Ordinary Shares Acquisiton 2019-05-28 7,983 $14.00 39,637 No 4 P Indirect By SV Life Sciences Fund V Strategic Partners. L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By SV Life Sciences Fund V, L.P.
No 4 C Indirect By SV Life Sciences Fund V, L.P.
No 4 C Indirect By SV Life Sciences Fund V Strategic Partners. L.P.
No 4 C Indirect By SV Life Sciences Fund V Strategic Partners. L.P.
No 4 P Indirect By SV Life Sciences Fund V, L.P.
No 4 P Indirect By SV Life Sciences Fund V Strategic Partners. L.P.
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Series A Preferred Shares Disposition 2019-05-28 874,709 $0.00 874,709 $0.00
Ordinary Shares Series B1 Preferred Shares Disposition 2019-05-28 623,196 $0.00 623,196 $0.00
Ordinary Shares Series A Preferred Shares Disposition 2019-05-28 18,485 $0.00 18,485 $0.00
Ordinary Shares Series B1 Preferred Shares Disposition 2019-05-28 13,169 $0.00 13,169 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.
  2. These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
  3. These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein